Abstract TS1-3: Proteogenomics and Clinical Translation

Improvements in breast cancer treatment are being achieved at an increasing pace in all three clinical subsets of the disease, namely ER+ HER2- (luminal), HER2+ (HER2-driven) and ER- PgR- and HER2- (triple negative). While these disease groupings served as useful approximations of the immense diversity of breast cancer when only endocrine therapy, chemotherapy and trastuzumab were available, the inadequacy of this disease classification is readily evident when set against the sophistication of our growing therapeutic armamentarium. What is on the horizon to replace our simple immunohistochemistry-based subtyping approaches to avoid misdiagnosis and consequent mismanagement? In this lecture I will make the argument that the advent of efficient and accurate protein mass spectrometry provides the “missing link” in ‘omics analysis that integrates information derived from next generation DNA and RNA analysis to create a more secure diagnostic conclusion. The new field of “clinical proteogenomics” validates proposed disease drivers, dissects complex amplicons, monitors signaling perturbations in response to targeted treatments and determines the activity of the immune microenvironment. The advent of cloud computing promotes the efficient delivery of individualized proteogenomic therapeutic road maps as a near-term possibility. Citation Format: MJ Ellis. Proteogenomics and Clinical Translation [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr TS1-3.